Biotech Values

[DewDiligence]

The_draft_guidance_is_affecting_the_market_today—e.g. HALO is -6% because of a provision in the document that says all formulations of an active ingredient will be treated as a single drug for “negotiation” purposes. I.e., under the draft guidance, HALO's subcutaneous reformulations of various biologics will not entitle those reformulations to circumvent the talons of the IRA.